S2694

SB-408124

≥98% (HPLC), solid

• Synonyme(s) : N-(6,8-Difluoro-2-methyl-4-quinolinyl)-N′-[4-(dimethylamino)phenyl]urea
• Formule empirique (notation de Hill) : C₁₉H₁₈F₂N₄O
• Numéro CAS: 288150-92-5
• Poids moléculaire : 356.37
• NACRES: NA.77
• PubChem Substance ID: 329824523
• UNSPSC Code: 51111800
• MDL number: MFCD06411575
• Assay: ≥98% (HPLC)
• Form: solid

Propriétés

• assay: ≥98% (HPLC)
• form: solid
• color: off-white
• solubility: DMSO: >10 mg/mL
• originator: GlaxoSmithKline
• storage temp.: 2-8°C
• SMILES string: CN(C)c1ccc(NC(=O)Nc2cc(C)nc3c(F)cc(F)cc23)cc1
• InChI: 1S/C19H18F2N4O/c1-11-8-17(15-9-12(20)10-16(21)18(15)22-11)24-19(26)23-13-4-6-14(7-5-13)25(2)3/h4-10H,1-3H3,(H2,22,23,24,26)
• InChI key: JTARFZSNUAGHRB-UHFFFAOYSA-N

Description

Application

SB-408124 was used to block orexin A-mediated cardiovascular effects in rats. It was used to study block the increase of endogenous glucose production mediated by bicuculline in rats.

Biochem/physiol Actions

SB 408124 is an OX₁ orexin receptor antagonist.

SB-408124 blocks the orexin type 1 receptor that stimulates the production of stress hormone in hypothalamus. It blocks orexin A-induced increase in arterial pressure and elevation of heart rate in rats. SB-408124 modulates phrenic nerve activity that is important in respiration.

Features and Benefits

This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Legal Information

Sold for research purposes under agreement from Glaxo­Smith­Kline

Informations sur la sécurité

• pictograms: GHS07
• signalword: Warning
• hcodes: H315,H319,H335
• pcodes: P261 - P264 - P271 - P280 - P302 + P352 - P305 + P351 + P338
• Hazard Classifications: Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
• target_organs: Respiratory system
• Classe de stockage: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable
• ppe: dust mask type N95 (US), Eyeshields, Gloves